Showing results (21-30 of 106) with videos related to
Sort By:
Pageof 11
Breast Cancer Research and Treatment|October 13, 2009
Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinomeLyndsay M Murrow, Sireesha V Garimella, Tamara L Jones, et al.Breast Cancer Research and Treatment|January 14, 2016
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and AxlJennifer L Dine, Ciara C O'Sullivan, Donna Voeller, et al.Plos One|November 13, 2012
Cbl-c ubiquitin ligase activity is increased via the interaction of its RING finger domain with a LIM domain of the paxillin homolog, Hic 5Philip E Ryan, Stephen C Kales, Rajgopal Yadavalli, et al.Archives of Pathology & Laboratory Medicine|July 2, 2024
Quality Assurance Model for Breast Cancer Prognostication Using the Modified Magee EquationsIan Lagerstrom, Daniel Neelon, Nena Wendzel, et al.Cancers|April 13, 2023
Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast CancerRohan Wedam, Yoshimi Endo Greer, David J Wisniewski, et al.Plos One|March 22, 2014
Recruitment of Cbl-b to B cell antigen receptor couples antigen recognition to Toll-like receptor 9 activation in late endosomesMargaret Veselits, Azusa Tanaka, Stanley Lipkowitz, et al.Plos One|May 24, 2019
Cbl interacts with multiple E2s in vitro and in cellsMariya S Liyasova, Ke Ma, Donna Voeller, et al.Molecular Cell|August 7, 2007
Structural basis for ubiquitin-mediated dimerization and activation of the ubiquitin protein ligase Cbl-bPascal Peschard, Guennadi Kozlov, Tong Lin, et al.Breast Cancer Research and Treatment|February 13, 2008
TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotypeMonzur Rahman, Sean R Davis, Janet G Pumphrey, et al.Plos One|July 2, 2019
Loss of function Cbl-c mutations in solid tumorsSilvano Rakeem Daniels, Mariya Liyasova, Stephen C Kales, et al.Pageof 11